# Samsara Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/samsara-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Hamburg, Germany
- Website: www.samsaratherapeutics.com
- Latest round: Series A (Sep 6, 2022)
- Investors on record: 2

## About

Samsara Therapeutics is focused on developing innovative therapeutics that activate autophagy to combat age-related neurodegenerative diseases, such as Alzheimer's and Parkinson's, enhancing patient care and quality of life.Founded in 2018 and headquartered in Hamburg, Germany, Samsara Therapeutics specializes in therapeutics aimed at activating autophagy to treat neurodegenerative disorders. The company has engaged in three deals, with its most recent funding round occurring on September 6, 2022. The firm was established by a team of individuals passionate about addressing the challenges of age-related diseases, although specific founder details are not available.Samsara Therapeutics specializes in the development of therapeutics that leverage autophagy activation to address age-related neurodegenerative diseases. The company's core product offerings include a range of drug candidates designed to enhance autophagy processes, particularly focusing on lysosomal biogenesis and autophagosome formation. These therapies aim to slow the progression of conditions such as Alzheimer's and Parkinson's diseases, ultimately improving patient outcomes. Samsara’s products target healthcare providers, research institutions, and patient advocacy organizations, emphasizing collaboration with stakeholders across the pharmaceutical and biotechnology sectors in North America and Europe.Samsara Therapeutics has secured substantial funding through partnerships and strategic investments, including a USD 25 mn Series A round led by Apollo Health Ventures. The revenue model is based on collaboration agreements with pharmaceutical companies and funding from patient advocacy groups, as well as potential licensing deals for its innovative drug candidates. Specific pricing structures are undisclosed, but transactions are expected to follow a partnership framework, aligning with its focus on developing impactful solutions for patients with neurodegenerative diseases.Samsara Therapeutics plans to utilize the funding raised in its Series A round to support the development of new drug candidates that are currently being designed to advance its therapeutic pipeline. The company is also targeting expansion into additional markets in North America and Europe, aiming for significant growth by the end of 2023. Recent funding will facilitate these initiatives, allowing for the enhancement of research and collaboration efforts as the firm continues to address the critical needs in neurodegenerative disease treatment.

## Funding rounds

- Series A, Sep 6, 2022 — FJ Labs
- Seed, Feb 26, 2019 — Apollo Health Ventures
- Seed, Sep 1, 2018 — Apollo Health Ventures

## Investors

- Apollo Health Ventures (https://capitalatlas.ai/funds/apollo-health-ventures) — Seed
- FJ Labs (https://capitalatlas.ai/funds/fj-labs) — Series A